Asymmetric limb weakness in Guillain-Barré syndrome: Three case reports

Ming Hu, Xiang Li, Hiu Yi Wong, Xun-Gang Feng, Yu-Zhong Wang, Guo-Rong Zhang

BACKGROUND
Guillain-Barré syndrome (GBS) is an autoimmune-mediated peripheral neuropathy characterized by symmetric weakness. Asymmetric weakness in GBS is uncommon and may be easily confused with other differential diagnoses. We herein present three cases of asymmetric GBS and review the literature on this atypical subtype of GBS in order to describe the characteristics of asymmetric GBS and to provide experience for clinicians.

CASE SUMMARY
Different from patients in the previous reports, our patients showed persistent asymmetric limb weakness from the onset to recovery phase. All three patients were serologically positive for antecedent infections. Two of the three cases had IgG antibodies against ganglioside GM1. Two patients received immunotherapy including intravenous immunoglobulin and plasma exchange, while one patient received only supportive treatment. Autoantibodies against gangliosides, asymmetry of congenital development of blood-nerve barrier and limb use may contribute to the development of asymmetric limb weakness in GBS.

CONCLUSION
Asymmetric GBS may be a rare clinical variant and should be considered when a patient develops acute and progressive asymmetric limb weakness. The differences in clinical features and prognosis between asymmetric GBS and classic
GBS deserve further investigation in a large study.

**Key Words:** Guillain-Barré syndrome; Asymmetric limb weakness; Autoantibodies; Blood-nerve barrier; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Atypical Guillain-Barré syndrome (GBS) with asymmetric limb weakness was rarely reported, which is easily confusing the diagnosis by clinicians. We herein present three patients diagnosed as GBS who suffered persistent asymmetric limb weakness from onset to recovery phase, two of which received immunotherapy in timely and had a good prognosis. Asymmetric blood-nerve barrier, ganglioside distribution or limb use may cause asymmetric GBS. To differentiate asymmetric GBS is important for an early treatment, which can lead to a good patient outcome and early recovery.

**Citation:** Hu M, Li X, Wong HY, Feng XG, Wang YZ, Zhang GR. Asymmetric limb weakness in Guillain-Barré syndrome: Three case reports. *World J Clin Cases* 2022; 10(6): 1896-1902
**URL:** https://www.wjgnet.com/2307-8960/full/v10/i6/1896.htm
**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i6.1896

**INTRODUCTION**

Guillain-Barré syndrome (GBS) is one of the most common causes of acute flaccid paresis with significant clinical heterogeneity[1]. At disease onset, most patients present with typical features of GBS such as symmetric tetraparesis, while some patients only present with incomplete variants, such as paraparetic or pharyngeal-cervical-brachial forms[2,3]. Recently, some atypical forms, such as asymmetric cranial nerve palsies, have been reported in patients with GBS[4]. However, asymmetric limb weakness in GBS is uncommon and may be confused with other conditions such as stroke. We herein describe three patients diagnosed with GBS who suffered from asymmetric limb weakness, review the literature and hypothesize the possible underlying mechanisms.

**CASE PRESENTATION**

**Chief complaints**

**Case 1:** A 56-year-old male worker presented with distal weakness of right upper and lower limb for five days and distal weakness of left upper and lower limb for two days.

**Case 2:** A 59-year-old male farmer presented with right upper and lower limb weakness for five days and left upper and lower limb weakness for four days.

**Case 3:** A 36-year-old male farmer presented with right upper and lower limb weakness for two days and left upper and lower limb weakness for one day.

**History of present illness**

**Case 1:** The patient had a history of pneumonia two weeks previously. At disease onset, he complained of right distal upper and lower limb weakness, loss of pain and temperature sensation in the right hand and foot, and could not walk independently. Three days later, the limb weakness and numbness extended to the left distal upper and lower limb, which continued to worsen until day 5.

**Case 2:** The patient denied antecedent infections. His clinical symptoms started five days ago with right upper and lower limb weakness, which had been extended to the left upper and lower limb on day 2 after onset. He complained of significant loss of pain and temperature sensation in bilateral hands and feet.

**Case 3:** The patient had a history of gastroenteritis 10 d before the onset of limb weakness. Two days ago, he complained of right upper and lower limb weakness and numbness, which was initially diagnosed with cerebral infarction at another hospital. The following day, his clinical symptoms progressed and the limb weakness and numbness extended to the left right upper and lower limb.
**History of past illness**
The three patients had no particular past history.

**Personal and family history**
The three patients had no particular individual or family history.

**Physical examination**
**Case 1:** The neurological examination revealed normal cranial nerves, 5/5 Medical Research Council (MRC) grade on proximal four limbs, 3/5 MRC on the right distal limb and 4/5 on the left distal limb. The tendon reflex of the four limbs was absent.

**Case 2:** Neurological examination on admission revealed bilateral distal and proximal limb weakness (for the distal, 1/5 MRC on the right and 2/5 MRC on the left; for the proximal, 3/5 MRC on the right and 4/5 on the left). Sensory examinations showed significant loss of pain and temperature sensation in bilateral hands and feet. The tendon reflex of four limbs was absent.

**Case 3:** On admission, neurological examination revealed weakness of both proximal and distal limbs, 3/5 MRC on bilateral proximal, 2/5 MRC on distal upper limbs, 2/5 MRC on the left distal lower limb and 1/5 on the right distal lower limb, deep tendon reflexes were decreased and he had loss of pain and temperature sensation in bilateral hands and feet.

**Laboratory examinations**
**Case 1:** Cerebrospinal fluid (CSF) analysis on day 10 showed normal cell counts (normal range, 0 to 8/mL) and increased protein concentration of 1.421 g/L (normal range, 0 to 0.45 g/L). Serological analysis of IgG antibodies against GM1, GM1b, GalNAc-GD1a, GD1a, GD1b, GQ1b, and GT1a were negative. Serological testing for IgM antibodies against influenza A virus and *Mycoplasma pneumoniae* were positive.

**Case 2:** CSF analysis on day 6 showed normal cell counts and increased protein levels (0.987 g/L). IgG antibodies against GM1 were positive. Serological testing for IgM antibodies against influenza A virus was positive.

**Case 3:** CSF analysis showed normal cell counts and increased protein concentration of 0.483 g/L on day 3 after onset. IgG antibodies against GM1 were positive. Serological testing for IgM antibodies against *Campylobacter jejuni* was positive.

**Imaging examinations**
**Case 1:** A nerve conduction study (NCS) on day 10 showed that the distal latencies of the median, ulnar and peroneal nerves were significantly increased, conduction velocities of the median, ulnar and tibial nerves were reduced and there was temporal dispersion of the median and tibial nerves. NCS results suggested demyelination. Magnetic resonance imaging (MRI) of the brain was normal. The spinal MRI was not performed.

**Case 2:** MRI of the spine was normal. He refused to undergo a NCS.

**Case 3:** A NCS on day 3 showed that the amplitudes of the median, ulnar, tibial and peroneal nerves were significantly reduced.

**FINAL DIAGNOSIS**
The three cases were diagnosed with GBS.

**TREATMENT**
**Case 1:** The patient received intravenous immunoglobulin which was initiated on day 10 at 2 g/kg/day for 5 d.

**Case 2:** The patient opted for supportive treatment due to cost.

**Case 3:** He was treated with plasma exchange (PE) every two days.
OUTCOME AND FOLLOW-UP

**Case 1:** On day 16, his limb weakness and numbness started to improve. On day 17, he was discharged. A follow-up at six months after onset showed 5/5 MRC on proximal four limbs, residual mild weakness of distal upper limbs (5/5 MRC on the left, 4/5 MRC on the right) and lower limbs (4/5 MRC bilateral).

**Case 2:** His clinical symptoms progressed and reached the nadir on day 9 after onset and he developed urinary retention. The MRC on four proximal limbs was 2/5, left distal limb muscle strength was 1/5 and right distal limb muscle strength was 0/5. The patient was discharged and returned to a local hospital on day 11. Six months later, a follow-up of this patient showed 2/5 MRC on four proximal limbs and 2/5 MRC on the left distal limb and 1/5 MRC on the right distal limb.

**Case 3:** His clinical signs showed no response to the first session of PE and symptoms progressed on day 4 after onset. The neurological examination showed 2/5 MRC on the left proximal limb and 3/5 on the right proximal limb, 1/5 MRC on the left and 2/5 MRC on the right distal lower limbs, and 1/5 on distal bilateral lower limbs. His sensory deficits in bilateral feet rose to bilateral legs. PE treatment proceeded as planned. On day 10 after onset, his weakness and numbness started to improve. Following PE, he was transferred to the rehabilitation ward for a course of electrical stimulation and physical rehabilitation. He was discharged on day 28. A follow-up at six months after onset showed asymmetric weakness on upper (4/5 MRC on the right and 3/5 on the left) and lower limbs (3/5 MRC on the right and 2/5 on the left).

DISCUSSION

Typical GBS is a mono-phasic polyneuropathy with acute onset symmetric cranial or limb weakness[5]. Asymmetric deficits, especially asymmetric limb weakness is easily confused with other neurological conditions such as stroke, demyelinating myelopathy, acute-onset chronic inflammatory demyelinating polyneuropathy[6], and beriberi neuropathy[7]. Although a study from Israel reported that asymmetric weakness accounted for 23% of atypical clinical findings of GBS in children[8], atypical GBS in adults with asymmetric limb weakness is rarely reported. Weakness or paresthesia in GBS may begin with symptoms in one limb, but most of the asymmetric symptoms at onset are transient and will progress to symmetric weakness at nadir[9,10]. Chi et al[11] reported a patient with axonal GBS who presented with acute onset of left hemiplegia and left sublingual nerve palsy mimicking stroke, of which the hemiplegia further progressed to tetraparesis within a few days. A Dutch study reported four patients who had asymmetric GBS[12], and three of these patients progressed to symmetric GBS within one week. Being different, both the case presented by Logullo et al[13] and our patients showed persistent asymmetric limb weakness starting from the acute phase until the recovery phase. In this report, we review the literature and summarize the clinical presentation of asymmetric GBS, including a case reported previously[13] and our cases reported in this paper (Table 1).

Although the exact mechanism of asymmetric deficits in GBS remains unclear, current evidence suggests a potential association between anti-ganglioside antibodies and asymmetric deficits in GBS. Stork et al[14] previously suggested that auto-antibodies against asialo-GM1 were associated with more pronounced motor deficits and asymmetry. Kim and Yuki[15] reported an unusual patient with hemiparetic GBS who had preceding gastroenteritis and anti-GD1a antibodies. In our patients, two out of three had autoantibodies against GM1. Anti-GM1 IgG antibodies binding to the nodal axolemma, which locates the GM1 and voltage-gated sodium channels, leads to the formation of membrane attack complex and disruption of sodium channels, which causes axonal impairment and nerve-conduction failure[16]. Binding of circulating antibodies onto the peripheral nerve myelin or axolemma relies on a rich blood supply and discontinuity of the blood-nerve barrier (BNB). Generally, the BNB along the nerve fiber is inhomogeneous and the distal and proximal are selectively more vulnerable to injury[17]. Manousakis et al[18] reported a patient with melanoma who developed multifocal and asymmetric polyradiculoneuropathy after ipilimumab treatment. The asymmetry of congenital development of BNB including the vascular endothelium permeability or asymmetric disruption of the BNB may be one of the underlying mechanisms leading to asymmetric limb weakness in GBS and antibodies-related peripheral neuropathy. Furthermore, the asymmetric distribution of the gangliosides may also cause the difference in limb involvement on both sides of patients with GBS. Finally, body position or limb use has also been suggested as a possible cause, which influences the initial distribution of weakness during crucial moments of influx of inflammatory factors into nerves[19]. All of our three patients were right-handed and their first clinical presentation at onset was all right-sided weakness. At nadir, the first two patients had more serious limb weakness on the right while the third patient had more serious limb weakness on the left. Our cases suggest a possible correlation between limb use and asymmetric GBS, which deserves further investigation.
### Table 1 Clinical features of patients with asymmetric Guillain-Barré syndrome

| Characteristics | Report by Logullo et al[13] | Present report |
|-----------------|-----------------------------|----------------|
|                 | Case 1                      | Case 1 | Case 2 | Case 3 |
| Age (yr)/sex    | 14/M           | 56/M   | 59/M   | 36/M   |
| Antecedent illness | Gastroenteritis            | Pneumonia | -      | Gastroenteritis |
| At entry        |                            |        |        |        |
| GBS disability score | 3                     | 2      | 4      | 4      |
| MRC sum-score   |                            |        |        |        |
| Left limb weakness | NA                    | 26     | 16     | 15     |
| Right limb weakness | NA                    | 22     | 10     | 12     |
| Sensory deficits | +                        | +      | +      | +      |
| Tendon reflex   | Normal                    | Areflexia | Areflexia | Hyporeflexia |
| Bulbar palsy    | -                         | -      | -      | -      |
| Ataxia          | -                         | -      | -      | -      |
| Cranial nerve involvement | -                  | -      | -      | -      |
| Albuminocytological dissociation in CSF | +              | +      | +      | +      |
| Cerebral magnetic resonance imaging | None          | -      | -      | -      |
| IgG antibodies to | GM1                    | -      | GM1    | GM1    |
| Nerve conduction studies | Axonal              | Demyelination | NA     | Axonal |
| Treatment       | IVIg                      | IVIg   | ST     | PE     |
| At nadir        |                            |        |        |        |
| Days between onset and nadir | 16              | 5      | 9      | 4      |
| GBS disability score | 4                   | 2      | 4      | 4      |
| MRC sum-score   |                            |        |        |        |
| Left limb weakness | NA                    | 26     | 8      | 8      |
| Right limb weakness | NA                    | 22     | 4      | 12     |
| Sensory deficits | +                        | +      | +      | +      |
| Tendon reflex   | Areflexia                | Areflexia | Areflexia | Areflexia |
| At six months after onset |                      |        |        |        |
| GBS disability score | 3                   | 2      | 4      | 4      |
| MRC sum-score   |                            |        |        |        |
| Left limb weakness | NA                    | 29     | 12     | 15     |
| Right limb weakness | NA                    | 26     | 8      | 21     |
| Sensory deficits | +                        | +      | +      | +      |
| Tendon reflex   | NA                       | Hyporeflexia | Areflexia | Hyporeflexia |

GBS: Guillain-Barré syndrome; MRC: Medical Research Council; CSF: Cerebrospinal fluid; IVIg: Intravenous immunoglobulin; PE: Plasma exchange; ST: Supportive treatment; NA: Not available.

### CONCLUSION

To sum up, asymmetric GBS is challenging the diagnosis criteria of GBS. To differentiate asymmetric GBS, especially the hemiplegia at onset with other similar conditions such as stroke, is important for an early treatment of IVIg or PE, which can lead to a good patient outcome and early recovery. Additionally, further study is necessary to investigate whether asymmetric GBS can be taken as a variant of GBS.
FOOTNOTES

Author contributions: Zhang GR and Hu M reviewed the literature and contributed to manuscript drafting; Li X and Feng XG played a major role in the acquisition of clinical data and the literature search; Wang YZ and Wong HY were responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.

Supported by Teacher Research Support Foundation of Jining Medical University, No. JYFC2018FKJ140; Natural Science Foundation Youth Project of Shandong Province, No. ZR2020QH110.

Informed consent statement: Informed written consent was obtained from the three patients for publication of this report.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Ming Hu 0000-0003-2901-4812; Xiang Li 0000-0001-8491-8836; Hui Yi Wong 0000-0001-5505-2447; Xun-Gang Feng 0000-0003-1009-2802; Yu-Zhong Wang 0000-0002-3145-9362; Guo-Rong Zhang 0000-0003-2901-4812.

S-Editor: Liu JH
L-Editor: A
P-Editor: Liu JH

REFERENCES

1. Willisson HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet* 2016; 388: 717-727 [PMID: 26948435 DOI: 10.1016/S0140-6736(16)00339-1]
2. van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC. Paraparetic Guillain-Barré syndrome. *Neurology* 2014; 82: 1984-1989 [PMID: 24808021 DOI: 10.1212/WN1.0000000000000481]
3. Pinal-Fernández I, Garrigasait Vilaseca V, Fernández-Codina A, Aranda Rodríguez S. [Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome]. *Medicina (B Aires)* 2014; 74: 474-475 [PMID: 25555009]
4. St Louis EK, Jacobson DM. Unilateral third nerve palsy caused by Guillain-Barré Syndrome. *Neurocrit Care* 2004; 1: 461-464 [PMID: 16174950 DOI: 10.1085/nc1.4-461]
5. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. *Ann Neurol* 1990; 27 Suppl: S21-S24 [PMID: 2194422 DOI: 10.1002/ana.410270707]
6. Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBs Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. *Neurology* 2010; 74: 1680-1686 [PMID: 20427754 DOI: 10.1212/WNL.0b013e3181e07d14]
7. Saini M, Lin W, Kang C, Umaphati T. Acute flaccid paralysis: Do not forget beriberi neuropathy. *J Peripher Nerv Syst* 2019; 24: 145-149 [PMID: 30569499 DOI: 10.1111/jnss.12297]
8. Yoshia-Orpaz N, Aharoni S, Rabie M, Nevo Y. Atypical Clinical Presentations of Pediatric Acute Immune-Mediated Polyneuropathy. *J Child Neurol* 2019; 34: 268-276 [PMID: 30674221 DOI: 10.1097/01.jcn.0000588132.106-108]
9. Ropper AH. The Guillain-Barré syndrome. *N Engl J Med* 1992; 326: 1130-1136 [PMID: 1552914 DOI: 10.1056/NEJM19920423326106]
10. Hargis MJ. Atypical Asymmetric Guillain-Barré Syndrome With Acute Rhabdomyolysis. *J Clin Neuromuscul Dis* 2017; 19: 96 [PMID: 29189556 DOI: 10.1097/CND.0000000000000175]
11. Chi MS, Ng SH, Chan LY. Asymmetric Acute Motor Axonal Neuropathy With Unilateral Tongue Swelling Mimicking Stroke. *Neurologist* 2016; 22: 106-108 [PMID: 27801771 DOI: 10.1097/NRL.0000000000000102]
12. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brightton criteria. *Brain* 2014; 137: 33-43 [PMID: 24163275 DOI: 10.1093/brain/awt285]
13. Logullo F, Manicone M, Di Bella P, Provinciali L. Asymmetric Guillain-Barré syndrome. *Neurology* 2006; 27: 355-359 [PMID: 17122947 DOI: 10.1212/01.wnl.0000220772.00710.52]
14. Stork AC, van der Pol WL, Franssen H, Jacobs BC, Notermans NC. Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. *J Neurol* 2014; 261: 1398-1404 [PMID: 24781837 DOI: 10.1007/s00415-014-7354-3]
15. Kim JE, Yuki N. Hemiparetic Guillain-Barré syndrome. *J Neurol Sci* 2016; 361: 131-132 [PMID: 26810530 DOI: 10.1007/s10072-016-3500-2]
16 Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, Hirata K, Baba H, Yuki N. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007; 27: 3956-3967 [PMID: 17428969 DOI: 10.1523/JNEUROSCI.4401-06.2007]

17 Seitz RJ, Heininger K, Schwendemann G, Toyka KV, Wechsler W. The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system. Acta Neuropathol 1985; 68: 15-21 [PMID: 3901654 DOI: 10.1007/BF00688950]

18 Manousakis G, Koch J, Sommerville RB, El-Dokla A, Harms MB, Al-Lozi MT, Schmidt RE, Pestronk A. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013; 48: 440-444 [PMID: 23447136 DOI: 10.1002/mus.23830]

19 Ropper AH. Further regional variants of acute immune polyneuropathy. Bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994; 51: 671-675 [PMID: 8018039 DOI: 10.1001/archneur.1994.00540190051014]
